New drug aims to lower dangerous fats in the blood
NCT ID NCT03747224
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new medicine called ARO-ANG3 in 93 people, including healthy volunteers and patients with high cholesterol or high triglycerides. The main goal was to check if the drug is safe and how the body processes it. This research helps determine if the drug should be tested in larger studies for managing lipid disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site 1
Nedlands, 6009, Australia
-
Research Site 2
Camperdown, New South Wales, 2050, Australia
-
Research Site 3
Adelaide, South Australia, 5000, Australia
-
Research Site 4
Grafton, Auckland, 1010, New Zealand
-
Research Site 5
Papatoetoe, Aukland, 2025, New Zealand
-
Research Site 6
Christchurch, 8011, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Plant-Based protein switch reshape your metabolism?
- A new multi-test approach may spot hidden blood vessel damage before symptoms appear
- Fish oil pills put to the test: can they tame high triglycerides?
- A diet designed for puerto rico: can traditional foods fight heart disease and diabetes?
- Weekly shot aims to tame dangerous fat levels in the blood
- Can a smartphone app help lower bad cholesterol?